GSK’s Pandemic Vaccine Will Test Swine-To-Bird Approval Transmission
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA agreed to infer GSK’s H5N1 vaccine’s effectiveness from the effectiveness of the adjuvanted H1N1 vaccine; agency’s Vaccines and Related Biological Products Advisory Committee will weigh in – and consider Dynavax’s hep B vaccine Heplisav – on Nov. 14.